SGLT-2 inhibitors have proven to be an effective treatment for glycemic control in type 2 diabetes mellitus. The indications for SGLT-2 have been expanding beyond glycemic control and now include chronic kidney disease and heart failure. These broadened indications mean more GIM physicians will be prescribing this class of medication to help improve the quality of life in patients. With this in mind, we are very pleased to publish this special supplement to the Canadian Journal of General Internal Medicine on the topic of SGLT-2 Therapy and its recent advancements and usage. These articles have been written by leading specialists, providing the reader with practical, clinically relevant and timely information.     Special thanks to Eli Lilly Canada and Boehringer Ingelheim Canada for their unrestricted support of this special issue.  Both companies had no input on the content, scope focus or author selection and were not involved in any review process.  

Original Research

The Why and How of SGLT2 Inhibitors in CKD

Megan Borkum, Adeera Levin
Abstract 483 | PDF Downloads 333 XML Downloads 656 HTML Downloads 164

Page 1-8

SGLT2 Inhibitor Use in Patients with Type 2 Diabetes Mellitus and Heart Failure

Sarah Fraser, Elizabeth Swiggum
Abstract 242 | PDF Downloads 173 XML Downloads 337 HTML Downloads 173

Page 9-16


SGLT2 Inhibitors in the Prevention and Treatment of Cardiovascular Disease

Michael Rheaume , Aditya Khetan, Marie Pigeyre
Abstract 548 | PDF Downloads 237 XML Downloads 225 HTML Downloads 147 | DOI

Page 22-29